$MDLN

Medline Inc.

Medline supplies medical-surgical products and supply chain solutions to customers across care settings, including hospitals, surgery centers, physician offices and post-acute facilities. Its two segments are Medline Brand, which offers products in Front Line Care, Surgical Solutions, and Laboratory and Diagnostics, and Supply Chain Solutions, which distributes products from third-party suppliers and provides services such as supply chain consulting, warehouse and technology management, third-party logistics, inventory rationalization, and route planning. As of December 31, 2025, Medline offers approximately 335,000 products across the two segments. Medline makes money by manufacturing and selling its branded products, distributing third-party products, and providing supply chain services. It also enters into multi-year Prime Vendor agreements to serve as customers’ primary distribution partner for most of their medical-surgical needs. Medline distributes through global facilities and its MedTrans truck fleet. Its headquarters are in Northfield, Illinois.

0
1
6

No SEC Form 4 filings for $MDLN in the last 30 days.

See all $MDLN insider activity →

Medline stockholders price secondary offering at $35.50

Medline Inc. (MDLN) announced a secondary offering of 60M Class A shares at $35.50 each by affiliated stockholders, with a 30-day option for underwriters to buy 9M more. The offering, expected to close Nov. 23, 2026, includes a $200M repurchase by Medline from selling stockholders. Medline is a medical-surgical products provider.

Medical supply giant recalls hospital beds amid reports of 7 deaths

Medline, the world's largest medical-surgical supplier, recalled hospital beds and related products due to 7 deaths and 35 injuries. The recall, announced on Oct. 14, 2026, includes beds, mattresses, and accessories sold between 2011 and 2026. Medline estimates costs of $50M-$200M, with potential legal and reputational risks. The company trades as MDLN on Nasdaq.

MDLN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 7 news stories mentioning MDLN (Medline Inc.). Coverage has skewed bearish: 0 bullish, 1 neutral, and 6 bearish.

Recent MDLN coverage spans financial news, corporate actions and regulation.

What's driving MDLN

  • Medline’s Backers Raise $2.1 Billion in Stock Offering, Bloomberg reports.

    bloomberg.com · Nov 18, 2026

  • The large secondary offering may dilute existing shareholders and put downward pressure on MDLN price.

    investing.com · Nov 18, 2026

  • Recall and product-line discontinuation raise near-term liability and regulatory risk, likely pressuring sentiment and earnings expectations.

    finance.yahoo.com · Nov 17, 2026

  • The large secondary offering will likely dilute existing shareholders and put downward pressure on the stock.

    investing.com · Nov 16, 2026

  • The FDA recalled Medline's medical beds and orthopedic mattresses after seven deaths and 35 injuries due to overheating and design flaws. The recall covers products sold in the US and Canada since 2011. The FDA advised users to disconnect beds and supervise patients.

    eadaily.com · Nov 14, 2026

AlphAI scores every news story that mentions MDLN with an AI model for sentiment and relevance, and aggregates insider trades from Medline Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $MDLN

Score

Medical supply giant recalls hospital beds amid reports of 7 deaths

Medline, the world's largest medical-surgical supplier, recalled hospital beds and related products due to 7 deaths and 35 injuries. The recall, announced on Oct. 14, 2026, includes beds, mattresses, and accessories sold between 2011 and 2026. Medline estimates costs of $50M-$200M, with potential legal and reputational risks. The company trades as MDLN on Nasdaq.

Medical supply giant Medline laying off 304 workers

Medline, a publicly traded medical supply company, is laying off 304 workers as part of a restructuring effort. The company reported 11% higher net sales but 29% lower net income for the first nine months of the year, citing higher operating expenses and inflation. Medline shares rose about 16% mid-Wednesday.

Related tickers